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Abstract
Impaired glucose tolerant (IGT) adults are at elevated risk for cardiovascular disease (CVD).
Exercise or metformin reduce CVD risk, but the efficacy of combining treatments is unclear. To
determine the effects of exercise training plus metformin, compared to each treatment alone, on
CVD risk factors in IGT adults. Subjects were assigned to: placebo (P), metformin (M), exercise
plus placebo (EP), or exercise plus metformin (EM) (8/group). In a double-blind design, P or
2000mg/d of M were administered for 12 weeks and half performed aerobic and resistance
training 3 days/week for approximately 60 minutes/day at 70% pre-training heart rate peak.
Outcomes included: adiposity, blood pressure (BP), lipids and high sensitivity C-reactive protein
(hs-CRP). Z-scores were calculated to determine metabolic syndrome severity. M and EM, but not
EP, decreased body weight compared to P (p <0.05). M and EP lowered systolic BP by 6% (p <
0.05), diastolic BP by 6% (p < 0.05), and hs-CRP by 20% (M: trend p = 0.06; EP: p < 0.05)
compared to P. Treatments raised HDL-cholesterol (p < 0.05; EM: trend p = 0.06) compared to P
and lowered triacyglycerol (p < 0.05) and metabolic syndrome Z-score compared to baseline (EP;
trend p = 0.07 and EM or M; p < 0.05). Although exercise and/or metformin improve some CVD
risk factors, only training or metformin alone lowered hs-CRP and BP. Thus, metformin may
attenuate the effects of training on some CVD risk factors and metabolic syndrome severity in IGT
adults.
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Introduction
Individuals with impaired glucose tolerance (IGT) are at elevated risk for cardiovascular
disease (CVD) (1, 2) and approximately half of these individuals have metabolic syndrome
(i.e. hypertensive, hyperglycemic, and dyslipidemic) (3). CVD risk is largely explained by
insulin resistance and excess body weight (4, 5). Treatments that raise insulin sensitivity or
lower body weight may lower CVD risk in individuals with IGT.
The mechanisms by which exercise lowers CVD risk likely involve increasing insulin
sensitivity (6, 7, 8) and lowering circulating lipids (e.g. triacylglycerol, low-density
lipoproteins, etc.), blood pressure, and C-reactive protein (9, 10, 11). Metformin treatment
can also increase insulin sensitivity (12, 13) and additionally, reduces fasting hyperglycemia
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and body weight (14, 15). Because the actions of exercise and metformin are potentially
additive, it has been suggested that individuals with IGT and at least 1 CVD risk factor (e.g.
hypertension, elevated triacylglycerol, low HDL, fasting hyperglycemia, etc.) be considered
for metformin treatment while participating in a regular exercise program (16). However,
the interactions between exercise and metformin on CVD risk factors have not been
systematically evaluated (17, 18). Adding to the uncertainty, we recently showed that
metformin blunted the effects of training on insulin sensitivity in men and women with IGT
(19). Since insulin resistance is believed to be a key underlying factor causing metabolic
syndrome (formerly syndrome X), it is important to understand the effects of metformin on
CVD risk after exercise training (20). Therefore, the purpose of this study was to determine
the effects of combining metformin with exercise training, compared to either treatment
alone, on reducing CVD risk factors in men and women with IGT. Given the opposing
effects on insulin sensitivity we observed in this same study group (19), we hypothesized




The effects of exercise training, metformin, or the combined treatment on cardiovascular
disease (CVD) risk factors were compared in 32 otherwise healthy men and women with
impaired glucose tolerance (IGT). Using a double-blind, placebo-controlled design,
individuals were tested before and after 12 weeks of placebo (P), metformin (M), exercise
training plus placebo (EP) or exercise training plus metformin (EM). Outcome measures
included body weight, waist circumference, blood pressure, and concentrations of blood
lipids, and high sensitivity C-reactive protein (hs-CRP) as well as metabolic syndrome
severity.
Subjects
These subjects were the same individuals who served as the study population in our prior
study on whole-body and hepatic insulin sensitivity (19). Subjects were recruited via
newspaper advertisements and flyers posted in the local community. Individuals (see Table
1) were non-smoking, weight stable (<5% weight change over last 3 months) and free of
CVD or type 2 diabetes. All subjects had impaired glucose tolerance (IGT). Individuals who
were using medications to manage blood pressure (M = 1; EP = 1; EM = 3) or cholesterol
(M = 1; EP = 1; EM = 1) were enrolled and continued treatment throughout the study.
Subjects were excluded from the study if they had any contraindications to metformin use
(e.g. respiratory disease, heart failure, renal/hepatic disease). All subjects were verbally
briefed about the study and signed informed consent documents approved by the
Institutional Review Board at the University of Massachusetts Amherst.
Screening
A 75 gram oral glucose tolerance test (OGTT) was used to screen individuals for IGT after a
minimum 5 hour fast. Individuals with glucose concentrations between 7.8–11.1mM (140–
199mg/dl) 120 minutes after consuming glucose met the criterion for IGT. Approximately
half of the subjects with IGT also had impaired fasting glucose (IFG), i.e. fasting glucose
concentrations between 5.5–6.9mM (100–125mg/dl). Most of the individuals in each
treatment group (M = 6; EP = 7 and EM = 6) also met ATP III criteria for metabolic
syndrome (21). Only 2 participants in the P group had metabolic syndrome. To minimize the
potential for Type-1 and Type-2 errors, we restricted the presentation of results to the 3
treatment groups
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VO2peak was used to characterize cardiorespiratory fitness, and 1-repetition max (1-RM)
tests were performed to determine strength as previously described (19).
Metformin or placebo protocol
A member of the research group, blinded to the protocol, administered pills to the subjects.
All subjects were instructed to take their pills with food to minimize potential side effects.
Subjects started treatment with 500 mg/d of metformin. The dose was increased 500 mg/d
each week until a standard clinical dose of 2000 mg/d was reached by week 4. This dose
was maintained for the ensuing 8 weeks of the protocol.
Exercise training
Subjects underwent supervised exercise sessions 3 days/week for 60–75 minutes per session
(approximately 190minutes/week total). Subjects cycled for 45 minutes at 70% of their pre-
training heart rate peak 3days/week, and performed whole-body resistance exercise at 70%
of the subject's 1-RM 2days/week. Subjects performed 2 sets of 12 repetitions for: chest
press, latissimus pull down, leg press, bicep curl, triceps pushdown, and upright rows.
Pedometers (Omron HJ112, Lake Forest, IL) were provided to all subjects and worn around
the waistband for 7 consecutive days at week 0, 6 and 12. These data were averaged to
characterize habitual ambulation. Habitual ambulation did not change in any group after the
intervention, nor were there differences across groups (data not shown).
Body weight, composition & waist circumference
Body weight was recorded without shoes, to the nearest 0.1kg on a calibrated scale, every 2
weeks at consistent times of day. Subjects were weighed in the fasted state for the first and
last measurements. As previously described (19) body fat and central fat (defined as fat mass
in the region bounded by the last floating rib to the top of the iliac crest/total fat mass) were
assessed by Dual-energy x-ray absorptiometry (DEXA; Lunar Prodigy, Madison, WI). Waist
circumference (WC) was measured to the nearest 0.25 cm with a plastic tape measure in the
standing position approximately 2 cm above the umbilicus.
Food intake
Food intake was assessed using 3-day food records at week 0, 6, and 12. Subjects selected 3
days of the week at the start of the study and the same 3 days of the week were used each
time food intake was assessed. Results were averaged across the 3 days to generate a single
value for energy intake at each time point. Participants were given verbal and written
instructions to accurately record the types and quantities of all food and beverages
consumed, including brand names and methods of food preparation. Food records were
analyzed (by the same investigator S.C.) using a commercial software program (Fitday, El
Segundo, California).
Blood pressure, lipids and high sensitivity-CRP
Subjects were provided isocaloric meals (~55% carbohydrate, 30% fat, and 15% protein
multiplied by 1.3 activity factor) 24 hours before baseline and week 12 measurements.
Energy intake was based on resting metabolic rate measurements for 30 minutes in the
supine position by indirect calorimetry (SensorMedics 800, Yorba Linda, CA). On the day
of testing, subjects reported to the laboratory after an overnight fast. Systolic (SBP) and
diastolic (DBP) blood pressure was determined once in the left arm using an automated
system (Mark of Fitness, Inc., Shrewsbury, NJ) after at least 5–10 minutes of quiet sitting.
Next, indwelling catheters were placed in a superficial vein of the forearm and fasting blood
samples were collected in 3 mL syringes. All vacutainers were kept on ice prior to blood
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collection. Blood samples for the analysis of glucose were transferred to vacutainers
containing sodium fluoride to inhibit glycolysis. Blood samples for the analysis of total
cholesterol (TC), high-density lipoproteins (HDL), and triacylglycerol (TAG) were collected
in vacutainers containing the anticoagulant EDTA. Serum samples for the analysis of hs-
CRP were collected in vacutainers containing a serum separator and allowed to clot for 15
minutes. Blood samples were centrifuged at room temperature for 10 minutes at 3000 RPM.
Samples were immediately aliquoted and transferred to a −80°C freezer until analysis.
Biochemical analyses
Fasting Plasma glucose (FPG), TC and HDL concentrations were determined enzymatically
(GL5 Analyzer, Analox Instruments, Lunenberg, MA). TAG concentrations were measured
by colorimetric assay (Sigma Aldrich, St. Louis, MO). Serum hs-CRP concentrations were
measured using high-sensitivity ELISA kit (Diagnostic Systems Laboratory, Webster, TX).
Calculations: Mean arterial pressure (MAP) was calculated as: MAP = (2/3DBP) +
(1/3SBP). The cardiac risk ratio (CRR) was calculated as TC divided by HDL (19). Low
density lipoprotein (LDL) was calculated using the Friedwald equation (LDL = TC – HDL –
(TAG* 0.2) (20). Metabolic syndrome Z-scores and ATP III criteria were calculated to
describe the efficacy of each treatment on metabolic syndrome severity and total number of
risk factors (18). Sex specific Z-scores were calculated as: male Z-score = [(40-HDL)/10.7]
+ [(TAG-150/88.5)] + [(FPG-100)/11.9] + [(WC-102)/14.3] + [(MAP-100)/8.8], and female
Z-score = [(50-HDL)/11.0] + [(TAG-150/88.5)] + [(FPG-100)/11.9] + [(WC-88)/13.6] +
[(MAP-100)/8.8].
Statistical Analysis
Data were analyzed using the R statistical software package (version 2.4.0, The R
foundation, Vienna, Austria, 2006). Baseline subject characteristics were measured across
conditions by one-way analysis of variance (ANOVA). There was no statistical difference in
any baseline value except DBP. Using baseline DBP as a co-variate did not affect the
response to the treatments. All other condition means were analyzed before and after the
intervention using 2-way (condition by test) repeated measures ANOVA. Because baseline
hs-CRP concentrations were not normally distributed, the data were log transformed for
statistical analysis. When there was a significant condition × test interaction, Tukey's Post
hoc analysis was used to detect differences across conditions. Paired t-tests were used to
assess pre- to post differences within a condition, including caloric intake, metabolic
syndrome Z-score and ATP III score. McNemar's test was used to assess metabolic
syndrome prevalence (i.e. yes/no) after each treatment (22). Pearson's correlation was used
to examine relationships between weight loss, cardiorespiratory fitness, CVD risk factors
and insulin sensitivity (19). Significant differences were accepted as α ≤ 0.05 and trends
were reported as 0.05 < α < 0.10.
Results
The raw data for fitness, body composition, fasting glucose and insulin have been published
previously (19). However, given the obvious relevance of those data to risk for CVD they
are summarized here for clarity.
Cardiorespiratory fitness and strength
Exercise training plus metformin (EM) and exercise training plus placebo (EP) increased
VO2peak by 10–20% compared to baseline and strength by approximately 15% compared to
baseline (19).
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Weight change, body composition & food intake
Metformin (M) and EM, but not EP, decreased body weight more than P (p < 0.05; Figure
1a). EM and EP also lowered percent body fat (P = −0.8 ± 0.6%; M = 0.1 ± 0.5%; EP = −2.2
± 0.8%; EM = −1.5 ± 0.7%) and central body fat (P = −0.6 ± 0.1%; M = −0.1 ± 0.6%; EP =
−1.4 ± 0.5%; EM = −1.9 ± 0.6%) by similar amounts. Waist circumference was 2–3% lower
after all 3 treatments compared to baseline (time effect: p < 0.01; Figure 1b), but was not
different across groups. Caloric intake was decreased by approximately 15% from baseline
for M (2107.3 ± 103.2 vs. 1819.8kcal; p < 0.05) and EM (2251.0 ± 135.7 vs. 1777.3 ±
130.2kcal; p < 0.05). Both EP (2292.0 ± 177.8 vs. 2149.2 ± 138.1kcal; p = 0.57) and P
(1923.22 ± 135.6 vs. 1861.3 ±144.5; p = 0.69) had no effect on intake.
Fasting plasma glucose and insulin
Exercise training and/or metformin had no effect on fasting glucose concentrations (P = −0.1
± 0.2mM; M = −0.2 ± 0.3mM; EP = 0.0 ± 0.3mM; EM = −0.4 ± 0.2mM). All 3 treatments
lowered fasting insulin concentrations (P = 1.5 ± 2.3uU/ml; M = −5.2 ± 1.9 uU/ml; EP =
−1.7 ± 0.7uU/ml; EM = −2.9 ± 1.5uU/ml), but there were no group differences.
Blood pressure
Compared to baseline, SBP and DBP increased with placebo (P; p < 0.05). M and EP
lowered SBP (p < 0.01), but all 3 treatments lowered DBP compared to P (p < 0.05; Table
2). Both M and EP decreased MAP compared to P (p < 0.05; Table 2) but there was no
change after EM.
High-sensitivity-C-reactive protein (hs-CRP)
EP and M, but not EM, lowered CRP by approximately 20% compared to P (EP: p < 0.05
and M: trend p = 0.06; Table 4).
Triacylglycerol (TAG) and Cholesterol
Compared to baseline, exercise and/or metformin lowered TAG by approximately 13%
(time effect: p < 0.05; Table 3), but there were no group differences. All 3 treatments raised
HDL cholesterol concentrations by 8–13% compared to P (M or EP; p < 0.05 and EM; trend
p = 0.06; Table 3). Each treatment also decreased the cardiac risk ratio (p < 0.05; Table 3).
Metabolic syndrome severity and prevalence
Exercise training and/or metformin reduced the metabolic syndrome Z-score (i.e. severity)
compared to baseline (EP; trend p = 0.07 and EM or M; p < 0.05; Figure 2a). Although each
treatment reversed metabolic syndrome prevalence (M = 6 to 1; EP = 7 to 4; EM 6 to 3; p <
0.05; Figure 2b), only EP and M reduced ATP III criteria (p < 0.05) compared to baseline
(Figure 2c).
Correlation Analysis
Increased cardiorespiratory fitness was significantly correlated with lower fasting glucose
concentrations (r = −0.38; p < 0.05) but not with any other CVD risk factor. Weight loss was
correlated with lower fasting insulin concentrations (r = 0.40; p < 0.05), caloric intake (r =
0.46; p < 0.05) and waist circumference (r = 0.60; p < 0.05). Reductions in TAG
concentrations were correlated with increased insulin sensitivity (r = −0.60; p < 0.05).
Lower hs-CRP concentrations were correlated with decreased systolic blood pressure (r =
0.46; p < 0.05).
Malin et al. Page 5














Metformin is not only used to treat type 2 diabetes, but it is also suggested to reduce
cardiovascular disease (CVD) risk factors in adults with impaired glucose tolerance (IGT)
(23). Previous work suggested that exercise with metformin reduced CVD risk factors more
than the respective treatments alone (17, 18), however, we observed no additive effect of
combining exercise with metformin to reduce CVD risk factors IGT men and women. There
are several possible differences between studies that may explain this. First, previous work
did not systematically compare the combined treatment to either exercise (17) or metformin
alone (18), thereby limiting the ability to know the effectiveness of the combined treatment
on CVD risk factors. Second, recommendations to increased physical activity were not
structured or supervised (18). Third, differences between HIV infected patients and IGT
pathophysiology (17) complicate comparing previous work to ours. Last, dietary
manipulations (i.e. low-fat diet) confound the ability to identify the independent effect of
exercise with metformin on CVD risk factors (18). Consistent with our previous work (19),
the current findings suggest that metformin may blunt some of the beneficial effects of
training to lower systolic blood pressure, hs-CRP and metabolic syndrome criteria.
Weight loss (i.e. fat loss) is associated with lower CVD risk. Although exercise training with
ad libitum food intake has mixed effects on weight loss (24, 25), combining it with
metformin has been shown to cause greater weight loss (26, 27, 28). We found that
combining metformin with exercise reduced body weight by approximately 4kg more than
exercise alone, however, this was not different than metformin alone. Neither metformin,
alone or with exercise, affected CVD risk factors (i.e. blood lipids, blood pressure, hs-CRP)
more than exercise alone. Comparable reductions in central body fat between the exercise
groups may explain the similar effects of exercise at reducing blood lipids (e.g. TAG and
TC) (19). However, metformin decreased blood lipids equivalently to either exercise group
without a change in central fat (measured by DEXA and waist circumference). Although we
report reductions in waist circumferences with metformin in this study, more direct
measures of central fat (e.g. MRI or CT scan) would be needed to confirm a true change in
visceral fat., Despite no strong correlation between weight loss or waist circumference and
CVD risk factors, we cannot rule out the possibility that fat loss explains at least some of the
metformin group outcomes. In either case, these results suggest that each treatment has
distinctive mechanisms for opposing CVD development.
Blood pressure is often lowered after exercise training (11), but the effects of metformin are
less consistent (13, 29, 30, 31). We found that metformin yielded little added benefit to the
effects of exercise training on lowering blood pressure and this outcome is consistent with
other work (18). Our data suggest that the interaction of metformin with exercise training
blunts reductions in systolic blood pressure, and these results may be related to changes in
cardiorespiratory fitness. Although there were no statistical differences in VO2peak between
the exercise groups, the attenuated rise in VO2peak (EM = 10% vs. EP = 20%) is worth
considering since it is consistent with our previous work in healthy adults (32). The smaller
rise in VO2peak is likely a result of either alterations in mitochondrial adaptations or
vascular blood flow. Although we did not directly measure endothelial function, we found
that exercise training or metformin alone, but not the combined treatment, reduced the
vascular inflammatory marker hs-CRP by approximately 20% compared to placebo. We
observed a significant correlation between the change in hs-CRP and systolic blood
pressure, suggesting that reduced systolic blood pressure may be related to decreased
vascular inflammation. Interestingly, metformin alone reduced both systolic blood pressure
and hs-CRP, but had no effect on VO2peak compared to placebo. This result strengthens the
hypothesis that there is a unique interaction between metformin and exercise on the
aforementioned outcomes that could have opposing effects on cardiovascular health. From
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this study, we cannot determine the mechanism by which the combined treatment blunted
reductions in systolic blood pressure or serum hs-CRP concentrations, but it may be related
to the interaction between nitric oxide synthesis and AMPK activation (33, 34). Exercise
combined with metformin was previously shown to blunt AMPK activation in skeletal
muscle (35). Since AMPK activation is important for nitric oxide production, it is possible
that the combined treatment blunted nitric oxide production and affected systolic blood
pressure and hs-CRP concentrations.
Although combining metformin with lifestyle modification lowered TAG concentrations
more than lifestyle modification alone in overweight insulin resistant adolescents (26, 28),
there was no additive effect in IGT adults (18). Consistent with Andreadis et al (18), we
found that exercise training and/or metformin had similar effects at lowering TAG
concentrations, despite exercise increasing VO2peak and reducing central body fat. The
decline in TAG concentrations across treatments was associated with increased insulin
sensitivity (r = −0.60; p < 0.05). Although we cannot prove causality or directionality from
this correlation, a possibility is that reductions in circulating TAG lead to improved
peripheral glucose uptake (36). Fasting non-esterified fatty acids (NEFA) concentrations
were elevated after exercise training with metformin, which could potentially explain the
blunted rise in insulin sensitivity (19). The incongruent finding between lower TAG and
higher NEFA concentrations with exercise plus metformin may relate to decreased NEFA
uptake in skeletal muscle and liver (37, 38) or increased lipolytic activity (39). We are not
able to discern which of the mechanisms account for elevated NEFA concentrations, but our
results support the beneficial effects of exercise to lower TAG and increase insulin
sensitivity (40). Whether exercise and/or metformin treatments have a direct impact on
reducing CVD incidence in individuals with IGT remains to be seen.
Approximately 50% of individuals with IGT have metabolic syndrome (3). Lifestyle
modification or metformin decrease metabolic syndrome prevalence (3), and the combined
treatment may have additive effects (18). In this study, we showed that structured exercise
training and/or metformin had similar effects on reducing metabolic syndrome severity (i.e.
Z-score; Figure 2a). The initial ATP III score was lower in the exercise with metformin
group, compared with either treatment alone. The lower baseline may have made it more
difficult to detect a significant improvement from baseline, and, only exercise training or
metformin alone reduced the number of subjects meeting ATP III criteria (Figure 2c). In
addition, although not statistically different, metformin decreased metabolic syndrome
prevalence more than the combined treatment (Figure 2b). Since the combined treatment did
not lower systolic blood pressure, an ATP III criteria factor, our findings suggest that the
interaction of metformin and exercise may oppose the reversal of metabolic syndrome in
IGT adults compared to metformin alone. We recognize that further work is needed given
the modest sample size in this study and our inability to compare treatment groups to
placebo because only 2 subjects in that group had metabolic syndrome. However, the novel
observation from this study is that combining exercise with metformin may have opposing
effects on cardiovascular health, which could be clinically significant (16).
In conclusion, we observed that combining metformin with structured exercise training did
not have additive effects on any CVD risk factor measured in this group of IGT adults.
Metformin may blunt some of the effects of exercise training on lowering systolic blood
pressure and hs-C-reactive protein and consequently contribute to preventing a decrease in
the number of metabolic syndrome risk factors. If our results are reproduced and
generalizable to men and women with IGT then the clinical utility of recommending the
combination of exercise and metformin for people with IGT may need to be re-evaluated.
Despite metformin alone reducing CVD risk factors comparably to exercise alone, the
improvements in cardiorespiratory fitness after exercise is one of the best predictors of CVD
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and early mortality. As a result, our findings highlight the overall positive effects of exercise
on lowering CVD risk in adults with IGT.
Acknowledgments
S.K.M, S.R.C, and B.B. contributed to the study design and data collection. S.K.M was primarily responsible for
data analysis and statistical integrity. J.N. contributed to data entry and data analysis. S.C. was solely responsible
for food data analysis. S.K.M, S.R.C, and B.B. wrote the manuscript and J.N and S.C. reviewed/edited the
manuscript. The authors would like to thank Kirsten Granados, Richard Viskochil, and Robert Gerber for technical
assistance and helpful discussion. B.B. receives consulting fees from Pfizer Global Inc. We thank all the dedicated
participants and research assistants for assistance on this project. This research was supported by NIH 5 R56
DK081038 Grant.
REFERENCES
(1). Blake D, Meigs J, Muller D, Najjar S, Andres R, Nathan D. Impaired glucose tolerance, but not
impaired fasting glucose, is associated with increased levels of coronary heart disease risk
factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004; 53(8):2095–
2100. [PubMed: 15277391]
(2). Festa A, D'Agostino R, Howard G, Mykknen L, Tracy RP, Haffner SM. Chronic subclinical
inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis
Study (IRAS). Circulation. 2000; 102(1):42–47. [PubMed: 10880413]
(3). Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of
metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes
Prevention Program randomized trial. Ann Intern Med. 2005; 142(8):611–619. [PubMed:
15838067]
(4). Haffner S. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003; 92(4A):
18J–26J.
(5). Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting
glycaemia: the current status on definition and intervention. Diabetic Med. 2002; 19(9):708–723.
[PubMed: 12207806]
(6). Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume
and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004; 96(1):101.
[PubMed: 12972442]
(7). Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, Galbo H. Insulin-stimulated muscle glucose
clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes. 1995;
44(9):1010–1020. [PubMed: 7657022]
(8). Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JFP, Dela F. Strength training increases
insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in
patients with type 2 diabetes. Diabetes. 2004; 53(2):294–305. [PubMed: 14747278]
(9). Durstine JL, Grandjean P, Cox C, Thompson P. Lipids, lipoproteins, and exercise. J Cardiopulm
Rehabil. 2002; 22(6):385–398. [PubMed: 12464825]
(10). Herder C, Peltonen M, Koenig W, Stfels K, Lindstrm J, Martin S, et al. Anti-inflammatory effect
of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia. 2009; 52(3):433–
442. [PubMed: 19130041]
(11). Bacon S, Sherwood A, Hinderliter A, Blumenthal J. Effects of exercise, diet and weight loss on
high blood pressure. Sports Med. 2004; 34(5):307–316. [PubMed: 15107009]
(12). Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin
increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2
diabetes. Diabetes. 2002; 51(7):2074–2081. [PubMed: 12086935]
(13). Lehtovirta M, Forsén B, Gullström M, Häggblom M, Eriksson JG, Taskinen MR, et al. Metabolic
effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001; 18(7):578–
583. [PubMed: 11553189]
Malin et al. Page 8













(14). Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate
metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996; 81(11):
4059–4067. [PubMed: 8923861]
(15). DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean
noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991; 73(6):1294–1301.
[PubMed: 1955512]
(16). Rhee M, Herrick K, Ziemer D, Vaccarino V, Weintraub W, Narayan KMV, et al. Many
Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care.
2010; 33(1):49–54. [PubMed: 19808929]
(17). Driscoll SD, Meininger GE, Lareau MT, Dolan SE, Killilea KM, Hadigan CM, et al. Effects of
exercise training and metformin on body composition and cardiovascular indices in HIV-infected
patients. AIDS. 2004; 18(3):465. [PubMed: 15090799]
(18). Andreadis EA, Katsanou PM, Georgiopoulos DX, Tsourous GI, Yfanti GK, Gouveri ET, et al.
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease
risk factors in overweight and obese subjects--the Carmos study. Exp Clin Endocrinol Diabetes.
2009; 117(4):175–180. [PubMed: 19053032]
(19). Malin S, Gerber R, Chipkin S, et al. Independent and Combined Effects of Exercise Training and
Metformin on Insulin Sensitivity in Individuals With Prediabetes. Diabetes Care. 2011; 35(1):1–
6.
(20). Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;
1995:473–486. [PubMed: 7624391]
(21). Johnson J, Slentz C, Houmard J, Samsa G, Duscha B, Aiken L, et al. Exercise training amount
and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction
Intervention through Defined Exercise). Am J Cardiol. 2007; 100(12):1759. [PubMed:
18082522]
(22). Fleiss, JL. Statistical methods for rates and proportions. John Wiley; New York: 1981. p. 114
(23). Bailey C. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Cardiovascular drugs and therapy. 2008; 22(3):215–224. [PubMed: 18288595]
(24). Church T, Martin C, Thompson A, Earnest C, Mikus C, Blair S. Changes in weight, waist
circumference and compensatory responses with different doses of exercise among sedentary,
overweight postmenopausal women. PloS one. 2009; 4(2):e4515–e4515. [PubMed: 19223984]
(25). Donnelly J, Hill J, Jacobsen D, Potteiger J, Sullivan D, Johnson S, et al. Effects of a 16-month
randomized controlled exercise trial on body weight and composition in young, overweight men
and women: the Midwest Exercise Trial. Arch Intern Med. 2003; 163(11):1343–1350. [PubMed:
12796071]
(26). Clarson C, Mahmud F, Baker J, Clark H, McKay W, Schauteet V, et al. Metformin in
combination with structured lifestyle intervention improved body mass index in obese
adolescents, but did not improve insulin resistance. Endocrine. 2009; 36(1):141–146. [PubMed:
19387874]
(27). Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program
in adolescents with insulin resistance. J Pediatr. 2008; 152(6):817–822. [PubMed: 18492523]
(28). Atabek M, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month,
randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;
21(4):339–348. [PubMed: 18556965]
(29). Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin
reduces both blood pressure and metabolic risk factors. J Intern Med. 1991; 229(2):181–187.
[PubMed: 1900072]
(30). Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, et al. Metformin
improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.
Diabetes Care. 1993; 16(10):1387–1390. [PubMed: 8269798]
(31). Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P, Rossi G, et al. Improvement of
insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-
resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab. 1996;
81(4):1568–1574. [PubMed: 8636369]
Malin et al. Page 9













(32). Braun B, Eze P, Stephens BR, Hagobian TA, Sharoff CG, Chipkin SR, et al. Impact of
metformin on peak aerobic capacity. Appl Physiol Nutr Metab. 2008; 33(1):61–67. [PubMed:
18347654]
(33). Verma S, Wang C, Li S, Dumont A, Fedak PWM, Badiwala M, et al. A self-fulfilling prophecy:
C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;
106(8):913–919. [PubMed: 12186793]
(34). Lira V, Brown D, Lira A, Kavazis A, Soltow Q, Zeanah E, et al. Nitric oxide and AMPK
cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol (Lond ). 2010; 588(Pt 18):3551.
[PubMed: 20643772]
(35). Sharoff C, Hagobian T, Malin S, Chipkin S, Yu H, Hirshman M, et al. Combining short-term
metformin treatment and one bout of exercise does not increase insulin action in insulin resistant
individuals. Am J Physiol Endocrinol Metab. 2010; 298(4):E815–823. [PubMed: 20071560]
(36). Kraus W, Slentz C. Exercise training, lipid regulation, and insulin action: a tangled web of cause
and effect. Obesity. 2009; 17(Suppl 3):S21–S26. [PubMed: 19927141]
(37). Smith AC, Mullen KL, Junkin KA, Nickerson J, Chabowski A, Bonen A, et al. Metformin and
exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat
diet-induced hyperglycemia. Am J Physiol Endocrinol Metab. 2007; 293(1):E172–181.
[PubMed: 17374701]
(38). Iozzo P, Hallsten K, Oikonen V, Virtanen K, Parkkola R, Kemppainen J, et al. Effects of
metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their
relation to visceral fat in type 2 diabetes. Diabetes Care. 2003; 26(7):2069–2074. [PubMed:
12832315]
(39). Koh H, Hirshman M, He H, Li Y, Manabe Y, Balschi J, et al. Adrenaline is a critical mediator of
acute exercise-induced AMP-activated protein kinase activation in adipocytes. Biochem J. 2007;
403(3):473–481. [PubMed: 17253964]
(40). Slentz C, Houmard J, Johnson J, Bateman L, Tanner C, McCartney J, et al. Inactivity, exercise
training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of
exercise intensity and amount. J Appl Physiol. 2007; 103(2):432–442. [PubMed: 17395756]
Malin et al. Page 10














Change in body weight over the 12 week protocol. ^Significant effect of M and EM
compared to P (p < 0.05). Significant effect of M(*) and EM(‡) compared to baseline (p <
0.05). Data are mean ± standard error of the mean.
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Change in waist circumference over the 12 week intervention. *Significant effect of time (p
< 0.05). Data are mean ± standard error of the mean.
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Metabolic syndrome severity before and after the 12 week intervention. *Pre to post was
statistically different by paired t-test; p < 0.05. $p = 0.07. Data are mean ± standard error of
the mean.
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Metabolic syndrome prevalence before and after the 12 week intervention. Prevalence refers
to the fraction of individuals with metabolic syndrome pre and post. *Pre to post was
statistically different by McNemar; p < 0.05. Data are frequency.
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ATP III score before and after the 12 week intervention. *Pre to post was statistically
different by paired t-test; p < 0.05. Data are mean ± standard error of the mean.
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Table 1
Subject Characteristics.
P M EP EM
Sex 6F/2M 4F/4M 5F/3M 5F/3M
Age (year) 49.8 ± 10.9 45.0 ± 7.5 45.4 ± 8.0 49.1 ± 6.6
BMI (kg/m2) 34.0 ± 6.3 33.9 ± 5.2 33.5 ± 4.1 31.2 ± 5.3
Body weight (kg) 93.5 ± 6.0 101.5 ± 5.8 95.5 ± 5.1 94.1 ± 6.5
VO2 peak (ml/kg-ffm/min) 41.2 ± 8.2 43.4 ± 10.3 45.7 ± 9.4 48.2 ± 4.9
Fasting Glucose (mM) 5.79 ± 0.57 5.58 ± 0.61 5.42 ± 0.42 5.46 ± 0.80
2-hour Glucose (mM) 9.38 ± 1.33 9.28 ± 1.53 10.23 ± 1.02 9.46 ± 1.70
Steps per day 4983.9 ± 2104.9 5028.1 ± 2047.7 5871.7 ± 1912.8 6444.6 ± 1529.9
No significant differences were observed between conditions.
Data are mean ± standard deviation.
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